Using Blood MicroRNAs to Detect Ovarian Cancer Stages
Author Information
Author(s): Kartikasari Apriliana Ellya Ratna, Michel-Lara Paul, Exton Hayden, Tekin-Sari Kaan, Alnefai Ebtesam Motlaq M., Mitchell Arnan, Sanchez-Huertas Cesar, Plebanski Magdalena
Primary Institution: RMIT University
Hypothesis
miRNA expression patterns shift with ovarian cancer progression and could facilitate stage-specific detection.
Conclusion
Circulating microRNAs can effectively detect ovarian cancer at specific stages, improving early detection and personalized treatment.
Supporting Evidence
- Circulating microRNAs showed 83.92% sensitivity and 89.82% specificity for detecting ovarian cancer.
- Combining miRNA panels with classical biomarkers improved detection sensitivity to 93.39%.
- miR-141, miR-200c, and miR-1246 were frequently used and showed sensitivity and specificity greater than 70%.
Takeaway
This study shows that tiny molecules in our blood can help doctors find ovarian cancer early, which is really important for treating it better.
Methodology
A systematic review and meta-analysis of 50 articles involving 209 studies assessing the diagnostic utility of circulating microRNAs for detecting ovarian cancer.
Potential Biases
The studies included were retrospective and may have selection bias.
Limitations
The accuracy is dependent on the methods of detection and the studies were predominantly focused on specific geographical populations, limiting generalizability.
Participant Demographics
The studies included participants from various countries, primarily in Eastern Asia and Europe, with varying sample sizes.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 76.75–80.86%
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website